Brain scans reveal how new combo drug curbs appetite
NCT ID NCT06267092
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study tested how CagriSema (a combination of cagrilintide and semaglutide) affects appetite and brain activity in 164 adults with overweight or obesity. Participants received either the drug, a placebo, or no medicine, and researchers measured appetite scores and brain responses using scans. The goal was to understand the mechanisms behind appetite control, not to achieve weight loss directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CagriSema (cagrilintide and semaglutide combination)
What this could lead to
If it works, this could help explain how this combination medicine reduces appetite and changes brain activity, potentially leading to better weight-loss treatments.
What could go wrong
This is an early Phase 1 study focused on measuring appetite and brain signals, not weight loss itself. Results may not translate to long-term benefits or apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, 10117, Germany